We have located links that may give you full text access.
JOURNAL ARTICLE
REVIEW
Current therapy for otitis media and criteria for evaluation of new antimicrobial agents.
Clinical Infectious Diseases 1992 June
Otitis media is the most commonly diagnosed disease in infants and children in the United States. For routine empirical treatment of uncomplicated acute otitis media, amoxicillin is the drug of choice. Persistence of signs and symptoms of infection during antimicrobial therapy calls for a change to an antibiotic effective against beta-lactamase-producing bacteria (e.g., trimethoprim-sulfamethoxazole, amoxicillin/clavulanate, or one of the newer oral cephalosporins) or performance of tympanocentesis/myringotomy or both. The most common nonsurgical and surgical methods currently employed for prevention of frequent recurrences are antimicrobial prophylaxis, myringotomy with insertion of a tympanostomy tube, and adenoidectomy. For patients who have otitis media with effusion for which treatment is indicated, antimicrobial agents have been shown to be effective; amoxicillin is preferred as initial therapy. Guidelines for evaluating new antimicrobial agents in the treatment of otitis media are presented in this report.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app